SweDeliver welcomes Janssen Pharmaceutica (BE) as new partner

2021-05-17

Janssen Pharmaceutica (BE) joins SweDeliver as a new industry partner. With international leading expertise in SweDeliver's research fields, Janssen Pharmaceutica will be an important and dedicated partner to the center.

Jens Ceulemans, Scientific Director Biopharmaceutics, Janssen
Jens Ceulemans, Scientific Director Biopharmaceutics, Janssen Pharmaceutica

Janssen Pharmaceutica, founded in 1953 by Dr. Paul Janssen, is headquartered in Beerse, Belgium. Owned by Johnson & Johnson, Janssen is today one of the world’s leading research-based pharmaceutical companies, conducting research and development activities related to a wide range of human medical disorders.

We teamed up with ‎Jens Ceulemans, Scientific Director Biopharmaceutics, and asked him what makes an international giant in the pharmaceutical industry – based in Belgium – engage in a Scandinavian drug delivery center?

“At Janssen we are driven by the fact that patients are waiting for breakthroughs. We focus on areas of medicine where the need is high, the science is compelling, and the opportunity to make a difference is great. In this respect, collaborating with top experts from academia and industry to expand and advance the science of drug delivery systems supporting oral, parenteral and pulmonary therapeutic applications is fully aligned with our mission.”

What key values will Janssen add to SweDeliver and its junior researchers?
“Janssen is a Credo-driven company centered around the general philosophy of our founder, Dr. Paul Janssen: ‘Patients are waiting’. This means our research and scientific insight will always be driven by patient needs. To achieve this, we have built a culture of innovation and execution, where we innovate on the critical path, take accountability for our actions, work with a sense of urgency, and openly communicate.”

What do you hope Janssen’s involvement in SweDeliver will generate in return?
“We hope our active involvement in SweDeliver will further strengthen our scientific rigor, culture of innovation, and value as a partner. In collaboration with your researchers, academic staff and other partners, we look forward to learning new approaches and gaining new insights all aimed at deriving excellent research results in a fully cooperative and respectful environment.”

What might SweDeliver add to European Life Science and Drug delivery?
“The research supported by SweDeliver has the potential to advance science in parenteral, oral and pulmonary delivery to a completely new level, which we believe will result in the availability of a new tools that will significantly facilitate further research in the European Life Sciences environment.”

FACTS SWEDELIVER

  • SweDeliver is a national competence center in drug delivery. With Uppsala University's Faculty of Pharmacy as the academic hub and 16 industrial partners, SweDeliver conducts research on parenteral, oral and pulmonary administration. 

MORE INFORMATION

CONTACT

Jens Ceulemans, Scientific Director BiopharmaceuticsJens Ceulemans, Scientific Director Biopharmaceutics
Janssen Pharmaceuticals
JCEULEM3@its.jnj.com


Christel Bergström, Center Director, Professor
Department of Pharmacy, Uppsala University
Christel.Bergstrom@farmaci.uu.se

Photo: Janssen Pharmaceutica, Mikael Wallerstedt

More news

Last modified: 2021-06-22